Journal of Neural Transmission

, 116:1483 | Cite as

Beyond tremor and rigidity: non-motor features of Parkinson’s disease

  • Matthias Löhle
  • Alexander Storch
  • Heinz Reichmann
Movement Disorders - Review Article

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease and primarily considered as a movement disorder defined by the presence of motor symptoms, such as bradykinesia, tremor and rigidity. However, it is nowadays widely accepted that PD is associated with a wide variety of non-motor features, which affect the vast majority of patients during the course of the disease and may even precede the onset of motor symptoms. The spectrum of these non-motor disturbances is very broad and comprises neuropsychiatric conditions, such as depression, dementia and hallucinations, as well as autonomic, sensory and sleep disorders. Physicians need to be aware of these non-motor features, since they have substantial impact on the health-related quality of life of PD patients, even ahead of motor symptoms. This article aims to provide an overview of frequently observed non-motor features in PD and discusses prospects and limitations of currently available options for symptomatic treatment of these disturbances.

Keywords

Parkinson’s disease Non-motor symptoms Depression Dementia Autonomic dysfunction 

References

  1. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999a) Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14(10):866–874PubMedGoogle Scholar
  2. Aarsland D, Larsen JP, Cummins JL, Laake K (1999b) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595–601PubMedGoogle Scholar
  3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48(8):938–942PubMedGoogle Scholar
  4. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56(6):730–736PubMedGoogle Scholar
  5. Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72(6):708–712PubMedGoogle Scholar
  6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392PubMedGoogle Scholar
  7. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263PubMedGoogle Scholar
  8. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287–293PubMedGoogle Scholar
  9. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson’s disease. J Neurol 255(Suppl 5):18–32PubMedGoogle Scholar
  10. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord 21(8):1119–1122PubMedGoogle Scholar
  11. Araki I, Kitahara M, Oida T, Kuno S (2000) Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol 164(5):1640–1643PubMedGoogle Scholar
  12. Ashour R, Jankovic J (2006) Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 21(11):1856–1863PubMedGoogle Scholar
  13. Ashour R, Tintner R, Jankovic J (2005) Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol 4(7):423–431PubMedGoogle Scholar
  14. Bakshi R (1996) Fluoxetine and restless legs syndrome. J Neurol Sci 142(1–2):151–152PubMedGoogle Scholar
  15. Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557 discussion 64PubMedGoogle Scholar
  16. Boeve BF, Silber MH, Ferman TJ (2003) Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4(4):281–284PubMedGoogle Scholar
  17. Bonin B, Vandel P, Kantelip JP (2000) Mirtazapine and restless leg syndrome: a case report. Therapie 55(5):655–656PubMedGoogle Scholar
  18. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211PubMedGoogle Scholar
  19. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F et al (2005) Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 20(12):1557–1563PubMedGoogle Scholar
  20. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52(5):438–445PubMedGoogle Scholar
  21. Brodsky MA, Godbold J, Roth T, Olanow CW (2003) Sleepiness in Parkinson’s disease: a controlled study. Mov Disord 18(6):668–672PubMedGoogle Scholar
  22. Buysse DJ, Reynolds CFIII, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213PubMedGoogle Scholar
  23. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R et al (2002) The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73(6):629–635PubMedGoogle Scholar
  24. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22(13):1901–1911PubMedGoogle Scholar
  25. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM (2007) Antidepressant treatment of veterans with Parkinson’s disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 20(3):161–165PubMedGoogle Scholar
  26. Chou KL, Evatt M, Hinson V, Kompoliti K (2007) Sialorrhea in Parkinson’s disease: a review. Mov Disord 22(16):2306–2313PubMedGoogle Scholar
  27. Comella CL (2002) Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA 287(4):509–511PubMedGoogle Scholar
  28. Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology 51(2):526–529PubMedGoogle Scholar
  29. Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A et al (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case–control study. Arch Neurol 65(9):1191–1194PubMedGoogle Scholar
  30. den Hartog Jager W, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 23:283–290Google Scholar
  31. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850–857PubMedGoogle Scholar
  32. Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W et al (2008) Lewy body dementia and Parkinson’s disease with dementia. J Neurol 255(Suppl 5):39–47PubMedGoogle Scholar
  33. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106(2):93–96PubMedGoogle Scholar
  34. Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502PubMedGoogle Scholar
  35. Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8):1237–1244PubMedGoogle Scholar
  36. Drake ME (1988) Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg 90(2):151–154PubMedGoogle Scholar
  37. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22(16):2314–2324PubMedGoogle Scholar
  38. Duggal HS, Mendhekar DN (2007) Clozapine-associated restless legs syndrome. J Clin Psychopharmacol 27(1):89–90PubMedGoogle Scholar
  39. Edwards LL, Quigley EM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 42(4):726–732PubMedGoogle Scholar
  40. Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16(6):1176–1177PubMedGoogle Scholar
  41. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 12(3):364–369PubMedGoogle Scholar
  42. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518PubMedGoogle Scholar
  43. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 (quiz 837)PubMedGoogle Scholar
  44. Ghazi-Noori S, Chung TH, Deane K, Rickards HE, Clarke CE (2003) Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev (3):CD003465Google Scholar
  45. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F (2007) A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord 22(11):1567–1572PubMedGoogle Scholar
  46. Global Parkinson’s Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67Google Scholar
  47. Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 63(4):434–440PubMedGoogle Scholar
  48. Gugger JJ, Wagner ML (2007) Rapid eye movement sleep behavior disorder. Ann Pharmacother 41(11):1833–1841PubMedGoogle Scholar
  49. Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15(7):490–494Google Scholar
  50. Hargrave R, Beckley DJ (1998) Restless leg syndrome exacerbated by sertraline. Psychosomatics 39(2):177–178PubMedGoogle Scholar
  51. Herting B, Schulze S, Reichmann H, Haehner A, Hummel T (2008) A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol 255(3):367–370PubMedGoogle Scholar
  52. Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19(9):1043–1049PubMedGoogle Scholar
  53. Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K et al (2002) Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25(8):905–909PubMedGoogle Scholar
  54. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738PubMedGoogle Scholar
  55. Horiguchi J, Yamashita H, Mizuno S, Kuramoto Y, Kagaya A, Yamawaki S et al (1999) Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol 14(1):33–36PubMedGoogle Scholar
  56. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH et al (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54(8):1596–1602PubMedGoogle Scholar
  57. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22(1):39–52PubMedGoogle Scholar
  58. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R (1995) Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 45(9):1691–1696PubMedGoogle Scholar
  59. Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 18(3):149–154PubMedGoogle Scholar
  60. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545PubMedGoogle Scholar
  61. Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Munneke M (2007) Impact of drooling in Parkinson’s disease. J Neurol 254(9):1227–1232PubMedGoogle Scholar
  62. Karatas M (2007) Restless legs syndrome and periodic limb movements during sleep: diagnosis and treatment. Neurologist 13(5):294–301PubMedGoogle Scholar
  63. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(12):1749–1752PubMedGoogle Scholar
  64. Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N et al (2004) Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 62(7):1224–1226PubMedGoogle Scholar
  65. Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S (1996) “Sniffin’ sticks”: screening of olfactory performance. Rhinology 34(4):222–226PubMedGoogle Scholar
  66. Kraus T, Schuld A, Pollmacher T (1999) Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol 19(5):478–479PubMedGoogle Scholar
  67. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006) Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21(5):704–707PubMedGoogle Scholar
  68. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18(4):414–418PubMedGoogle Scholar
  69. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H et al (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55(4):539–544PubMedGoogle Scholar
  70. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H et al (2002a) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51(6):722–729PubMedGoogle Scholar
  71. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B et al (2002b) Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 17(6):1221–1226PubMedGoogle Scholar
  72. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76(3):343–348PubMedGoogle Scholar
  73. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61(9):1279–1281PubMedGoogle Scholar
  74. Magerkurth C, Schnitzer R, Braune S (2005) Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res 15(2):76–82PubMedGoogle Scholar
  75. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(2):178–183PubMedGoogle Scholar
  76. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18(6):685–688PubMedGoogle Scholar
  77. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52(7):695–701PubMedGoogle Scholar
  78. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26(8):1049–1054PubMedGoogle Scholar
  79. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886–892PubMedGoogle Scholar
  80. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N (2004) Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 111(10–11):1447–1453PubMedGoogle Scholar
  81. Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 29(6):331–337PubMedGoogle Scholar
  82. Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid Y (2003) Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness. Neurology 60(9):1553–1554PubMedGoogle Scholar
  83. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K et al (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):996–1002PubMedGoogle Scholar
  84. Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G et al (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 23(Suppl 2):S89–S90PubMedGoogle Scholar
  85. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R et al (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27(4):153–156PubMedGoogle Scholar
  86. Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23(10):1361–1369PubMedGoogle Scholar
  87. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17(5):1031–1035PubMedGoogle Scholar
  88. Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 62(1):37–40PubMedGoogle Scholar
  89. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 20(8):958–963PubMedGoogle Scholar
  90. Paik IH, Lee C, Choi BM, Chae YL, Kim CE (1989) Mianserin-induced restless legs syndrome. Br J Psychiatry 155:415–417PubMedGoogle Scholar
  91. Papapetropoulos S, Mash DC (2005) Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol 252(7):753–764PubMedGoogle Scholar
  92. Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D et al (2008) A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol 8:21PubMedGoogle Scholar
  93. Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely, and Jones, LondonGoogle Scholar
  94. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord 18(6):659–667PubMedGoogle Scholar
  95. Perroud N, Lazignac C, Baleydier B, Cicotti A, Maris S, Damsa C (2007) Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry 29(1):72–74PubMedGoogle Scholar
  96. Pinninti NR, Mago R, Townsend J, Doghramji K (2005) Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol 25(6):617–618PubMedGoogle Scholar
  97. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM et al (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695PubMedGoogle Scholar
  98. Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM (2006) The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 253(2):171–175PubMedGoogle Scholar
  99. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22(3):313–318PubMedGoogle Scholar
  100. Razmy A, Lang AE, Shapiro CM (2004) Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61(1):97–102PubMedGoogle Scholar
  101. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23(2):183–189 quiz 313PubMedGoogle Scholar
  102. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382PubMedGoogle Scholar
  103. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 56(12):556–559PubMedGoogle Scholar
  104. Richard IH, Kurlan R (1997) A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 49(4):1168–1170PubMedGoogle Scholar
  105. Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F et al (2008) Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 255(2):255–264PubMedGoogle Scholar
  106. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173PubMedGoogle Scholar
  107. Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36(8):1130–1133PubMedGoogle Scholar
  108. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A (1996) Restless legs syndrome and paroxetine. Acta Psychiatr Scand 94(6):482–484PubMedGoogle Scholar
  109. Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2):388–393PubMedGoogle Scholar
  110. Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E et al (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69(23):2162–2169PubMedGoogle Scholar
  111. Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J et al (2006) Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov Disord 21(9):1432–1438PubMedGoogle Scholar
  112. Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16(3):507–510PubMedGoogle Scholar
  113. Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43(9):1690–1692PubMedGoogle Scholar
  114. Stevens S, Cormella CL, Stepanski EJ (2004) Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 27(5):967–972PubMedGoogle Scholar
  115. Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 10(3):337–340PubMedGoogle Scholar
  116. Tan EK, Lum SY, Fook-Chong SM, Teoh ML, Yih Y, Tan L et al (2002) Evaluation of somnolence in Parkinson’s disease: comparison with age- and sex-matched controls. Neurology 58(3):465–468PubMedGoogle Scholar
  117. Tandberg E, Larsen JP, Karlsen K (1998) A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 13(6):895–899PubMedGoogle Scholar
  118. Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 14(6):922–927PubMedGoogle Scholar
  119. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340(10):757–763Google Scholar
  120. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS et al (2008) Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23(16):2267–2302PubMedGoogle Scholar
  121. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139PubMedGoogle Scholar
  122. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69(4):333–341PubMedGoogle Scholar
  123. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312PubMedGoogle Scholar
  124. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76(3):217–221PubMedGoogle Scholar
  125. Weintraub D, Stern MB (2005) Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 13(10):844–851PubMedGoogle Scholar
  126. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2004) Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 52(5):784–788PubMedGoogle Scholar
  127. Wetter TC, Brunner J, Bronisch T (2002) Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 35(3):109–111PubMedGoogle Scholar
  128. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J et al (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69(4 Suppl 1):S14–S22PubMedGoogle Scholar
  129. Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D et al (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Matthias Löhle
    • 1
  • Alexander Storch
    • 1
  • Heinz Reichmann
    • 1
  1. 1.Department of NeurologyUniversity Hospital “Carl Gustav Carus”, Dresden University of TechnologyDresdenGermany

Personalised recommendations